Milestone Asset Management LLC Buys Shares of 41,725 Bristol Myers Squibb Company $BMY

Milestone Asset Management LLC acquired a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) in the 4th quarter, Holdings Channel reports. The fund acquired 41,725 shares of the biopharmaceutical company’s stock, valued at approximately $2,251,000.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Kanawha Capital Management LLC boosted its position in shares of Bristol Myers Squibb by 29.1% during the fourth quarter. Kanawha Capital Management LLC now owns 45,352 shares of the biopharmaceutical company’s stock worth $2,446,000 after buying an additional 10,233 shares during the period. HB Wealth Management LLC boosted its position in shares of Bristol Myers Squibb by 12.1% during the fourth quarter. HB Wealth Management LLC now owns 87,126 shares of the biopharmaceutical company’s stock worth $4,700,000 after buying an additional 9,429 shares during the period. Caprock Group LLC boosted its position in shares of Bristol Myers Squibb by 20.3% during the fourth quarter. Caprock Group LLC now owns 76,135 shares of the biopharmaceutical company’s stock worth $4,107,000 after buying an additional 12,822 shares during the period. Kingswood Wealth Advisors LLC boosted its position in shares of Bristol Myers Squibb by 3.1% during the fourth quarter. Kingswood Wealth Advisors LLC now owns 40,432 shares of the biopharmaceutical company’s stock worth $2,181,000 after buying an additional 1,212 shares during the period. Finally, KLP Kapitalforvaltning AS boosted its position in shares of Bristol Myers Squibb by 2.3% during the fourth quarter. KLP Kapitalforvaltning AS now owns 1,563,158 shares of the biopharmaceutical company’s stock worth $84,317,000 after buying an additional 35,600 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Stock Performance

BMY opened at $58.84 on Thursday. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The firm has a market capitalization of $120.13 billion, a PE ratio of 17.05, a PEG ratio of 0.17 and a beta of 0.27. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The business’s 50-day simple moving average is $59.74 and its 200 day simple moving average is $53.95.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. During the same quarter in the previous year, the company posted $1.67 EPS. The business’s revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts expect that Bristol Myers Squibb Company will post 6.28 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.3%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 73.04%.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Atrium Therapeutics announced it earned a $15M development milestone payment from Bristol Myers Squibb under their cardiovascular collaboration — a sign the partnered program advanced to a pre-agreed development candidate milestone, which de-risks that asset and validates BMS’s pipeline investments. Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb
• Positive Sentiment: Barclays reportedly initiated (or reiterated) a Buy on BMY — analyst upgrades/Buy ratings can lift the stock by increasing demand and signaling confidence in growth/earnings trajectory. Bristol-Myers Squibb (BMY) Receives a Buy from Barclays
• Positive Sentiment: Buy-side and independent outlets (Zacks, MSN) are publishing bullish/tactical takes — calling BMY a value/momentum name vs. peers and highlighting its cheaper valuation and improving earnings outlook, which supports longer-term investor interest. Here’s Why Bristol Myers Squibb (BMY) is a Strong Value Stock
• Neutral Sentiment: Bernstein kept a Hold on BMY — a Hold is not a fresh negative but tempers upside from upgrades and signals that some analysts remain cautious on near-term catalysts. Bernstein Remains a Hold on Bristol-Myers Squibb (BMY)
• Neutral Sentiment: Earnings are expected this week — scheduled quarterly results are a primary near-term catalyst (guidance and product trends will matter most given last quarter’s EPS miss and FY2026 guidance). Investors are positioning ahead of the print. Bristol Myers Squibb (BMY) Expected to Announce Quarterly Earnings on Thursday
• Neutral Sentiment: Geronimo Power’s new solar project will supply power under PPAs that include Bristol Myers Squibb — a sustainability/operational-cost item that is positive long-term but unlikely to move the stock materially near-term. Geronimo Power commences operations at 270MW Blevins Solar Project
• Negative Sentiment: Some market commentaries and sector pieces flagged downbeat forecasts or questioned certain pharma names — negative analyst notes or skeptical headlines can pressure BMY, especially when coupled with prior EPS misses or generic/competitive risks. 1 Unpopular Stock That Should Get More Attention and 2 We Question

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BMY. Scotiabank reaffirmed a “sector perform” rating and set a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a research report on Friday, January 9th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Leerink Partners upped their price objective on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Citigroup upped their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. Finally, UBS Group reaffirmed a “buy” rating and set a $70.00 price objective on shares of Bristol Myers Squibb in a research report on Friday, March 6th. Eight research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $61.31.

Insider Transactions at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.